Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat

Diabetologia

Volumn 47, Issue 8, 2004, Pages 1385-1395

  Alderson, N L ^a   Chachich, M E ^a   Frizzell, N ^b   Canning, P ^b   Metz, T O ^a   Januszewski, A S ^a   Youssef, N N ^a   Stitt, A W ^b   Baynes, J W ^a,c   Thorpe, S R ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; AGE ALE; AGE ALE inhibitor; Antioxidants; Enalapril; Lipoic acid; Nephropathy; Pyridoxamine; Vitamin E

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANTIOXIDANT; CHOLESTEROL; COLLAGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; LIPID; MESSENGER RNA; PYRIDOXAMINE; SCLEROPROTEIN; STREPTOZOCIN; THIOCTIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; FEMALE; GLOMERULUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY FUNCTION; KIDNEY TUBULE; LIPID OXIDATION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; SKIN; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; FIBRONECTINS; KIDNEY FUNCTION TESTS; LIPIDS; POLYMERASE CHAIN REACTION; PYRIDOXAMINE; RATS; RATS, SPRAGUE-DAWLEY; THIOCTIC ACID; VITAMIN E;

EID: 4544349321     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1474-8     Document Type: Article

References (43)

1. Raj DSC, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a nephrologist's perspective. Am J Kid Dis 35:365-380
2. Stitt AW, Jenkins AJ, Cooper ME (2002) Advanced glycation end products and diabetic complications. Expert Opin Invest Drugs 11:1205-1223
3. Dyer DG, Dunn JA, Thorpe SR (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469
4. Ceriello A (1999) Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12:42-46
5. Nishikawa T, Edelstein D, Du XL et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404:787-790
6. Suzuki D, Miyata T (1999) Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38:309-314
7. Alderson NA, Chachich ME, Youssef NN et al. (2003) Pyridoxamine limits dyslipidemia, hypertension and early nephropathy in obese Zucker (fatty) rats. Kidney Int 63:2123-2133
8. Nilsson BO (1999) Biological effects of aminoguanidine: an update. Inflamm Res 48:509-515
9. Miyata T, Ueda Y, Asahi K et al. (2000) Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11:1719-1725
10. Degenhardt TP, Alderson NL, Arrington DD et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950
11. E-(carboxymethyl)-lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23:1539-1544
12. Forbes JM, Cooper ME, Thallas V et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282
13. Nangaku M, Miyata T, Sada T et al. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212-1222
14. Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M (2003) Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 419:55-62
15. Way KJ, Katai N, King GL (2001) Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945-959
16. Frank RN (2002) Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 133:693-698
17. Usui H, Shikata K, Matsuda M et al. (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265-272
18. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110-2120
19. Koya D, Lee IK, Ishii H, Kanoh H, King GL (1997) Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 8:426-435
20. Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK (1997) Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405-1414
21. Kim SS, Gallaher DD, Csallany AS (2000) Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats. Lipids 35:1225-1237
22. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA (2000) Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1015
23. Melhem MF, Craven PA, Liachenko J, DeRubertis FR (2002) Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 13:108-116
24. Melhem MF, Craven PA, Derubertis FR (2001) Effects of dietary supplementation of α-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 12:124-133
25. Obrosova IG, Fathallah L, Liu E, Nourooz-Zadeh J (2003) Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Rad Biol Med 34:186-195
26. Packer L, Kraemer K, Rimbach G (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17:888-895
27. Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413-1416
28. E-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205-1210
29. Requena JR, Fu M-X, Ahmed MU et al. (1997) Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322:317-325
30. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660
31. Kreisberg JI, Karnovsky MJ (1983) Glomerular cells in culture. Kidney Int 23:439-447
32. Abrass CK, Spicer D, Raugi GK (1994) Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 46:613-620
33. Peterson GL (1979) Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 100:201-220
34. Requena JR, Price DL, Thorpe SR, Baynes JW (1999) Measurement of pentosidine in biological samples. In: Barnett Y, Barnett CR (eds) Methods in molecular medicine, vol 38: Aging, methods and protocols. Humana Press, N.J., pp 209-217
35. Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB, Stitt AW (1999) Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun 262:333-340
36. Simpson DA, Feeney S, Boyle C, Stitt AW (2000) Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 6:178-183
37. Stitt A, Gardiner TA, Alderson NL et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-2832
38. Thorpe SR, Alderson NL, Chachich ME et al, (2002) Role of dyslipidemia and AGE/ALE formation in the progression of nephropathy and retinopathy in STZ-diabetic rats. Excerpta Med 1245:169-173
39. Mogyorosi A, Kapoor A, Isono M, Kapoor S, Sharma K, Ziyadeh FN (2000) Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy. Nephron 86:234-235
40. Ziyadeh FN, Hoffman BB, Han DC et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020
41. Miyata T, Ueda Y, Horie K et al. (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53:416-422
42. Fujita A, Ueda Y, Suzuki D, Miyata T, Sakai H, Saito A (2002) Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron 91:688-694
43. Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413-1416